adebrelimab + SHR-8068

This is a combination of two investigational monoclonal antibodies: **adebrelimab**, an anti-PD-L1 antibody, and **SHR-8068**, an anti-CTLA-4 antibody. Both are immune checkpoint inhibitors designed to enhance the antitumor immune response. The combination is being developed primarily by Jiangsu Hengrui Pharmaceuticals and is under clinical development as dual immunotherapy, sometimes in combination with chemotherapy or anti-angiogenic agents, for multiple solid tumors including colorectal cancer, biliary tract cancer, non-small cell lung cancer, and hepatocellular carcinoma. Adebrelimab acts by blocking PD-L1 to reactivate T-cell-mediated antitumor immunity. SHR-8068 acts by inhibiting CTLA-4, a negative regulator of T-cell activation, further boosting immune response against tumors[3][5][6]. Early clinical studies suggest that the combination may improve efficacy compared to either agent alone in certain cancer types, with ongoing trials assessing safety, tolerability, and antitumor activity[3][6][7].

Other names

adebrelimab + SHR-8068